Category - Markets

Maxim Group slashed its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $2 from $4, but maintained its “buy” rating, after the company reported fiscal second quarter results. The stock closed at $1.32 on May 9...

Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5. Tocagen is...

BTIG upgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “sell,” saying the shares have fallen below a prior $4 price target. The stock closed at $3.98 on May 5. “While there is no change to our thesis on T2Candida...

Canaccord Genuity raised its price target for Endologix (NASDAQ:ELGX) to $7 from $5.75 but maintained a “hold” rating. The stock closed at $7.34 on May 4. Analyst Jason Mills writes that while Endologix’s first quarter...

RBC Capital Markets initiated coverage of TSO3 (TSX:TOS) with an “outperform, speculative risk” rating and $4.25 (Canadian) price target. The stock closed at $3.09 on May 2. TSO3 recently commercialized a highly...

Leerink downgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “market perform” from “outperform” and slashed its price target to $10 from $29, following a corporate update highlighting an unusual preclinical safety...

Roth Capital Partners raised its price target for Conatus Pharmaceuticals (NASDAQ:CNAT) to $12 from $4, reflecting a revised valuation. The stock closed at $7.58 on April 21. Analyst Sa’ar Yaniv writes that the revision...

BTIG initiated coverage of Cascadian Therapeutics (NASDAQ:CASC) with a “buy” rating and $13 price target. The stock closed at $3.92 On April 20. Cascadian is focused on the development of Tucatinib, an oral, highly...

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19. “We expect a number of events over the coming 12 months to drive investor...

Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14. Poxel’s Imeglimin has demonstrated promising efficacy for the treatment...